FindTrial
Sign In

THE COMPARATIVE STUDY OF EFFICACY BETWEEN CREAM CONTAINING SPENT GRAIN WAX, SHEA BUTTER, ARGANIA SPINOSA KERNEL OIL, TAPIOCA STARCH AND 1% HYDROCORTISONE CREAM IN THE TREATMENT AND PREVENTION OF INTERTRIGO

THE COMPARATIVE STUDY OF EFFICACY BETWEEN CREAM CONTAINING SPENT GRAIN WAX, SHEA BUTTER, ARGANIA SPINOSA KERNEL OIL, TAPIOCA STARCH AND 1% HYDROCORTISONE CREAM IN THE TREATMENT AND PREVENTION OF INTERTRIGO

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200719001
Enrollment
Unknown
Registered
2020-07-19
Start date
2019-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intertigo

Interventions

CREAM CONTAINING SPENT GRAIN WAX&#44
SHEA BUTTER&#44
ARGANIA SPINOSA KERNEL OIL&#44
TAPIOCA STARCH,1% HYDROCORTISONE CREAM
Experimental Other,Active Comparator Drug
STIMU&#45
TEX AS,HCC

Sponsors

Zuellig Pharma CO., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Months to 60 Years

Inclusion criteria

Inclusion criteria: Participants must be one month to sixty years old before the time of study recruitment and had one or more erythematous rashes at intertriginous areas. These lesions have to be performed necessary tests or diagnosed by dermatologists as intertrigo.

Exclusion criteria

Exclusion criteria: Other common intertriginous rashes were excluded, such as erythrasma by clinical and Wood’s lamp examination, candidiasis by clinical and potassium hydroxide preparation. Contact dermatitis, atopic dermatitis, inverse psoriasis, and seborrheic dermatitis were also excluded by clinical and history taking. Furthermore, subjects who have a history of allergic to corticosteroid, STIMU-TEX AS, or other ingredients in our creams should not participate in this study. In terms of safety, pregnant or lactated women also excluded. Topical and systemic anti-inflammatory agents like corticosteroid, NSAIDs, or antihistamine must stop before starting the protocol for two weeks and four weeks, respectively.

Design outcomes

Primary

MeasureTime frame
Erythema 0,1,2 and 4 week Visual assessment of erythema—

Secondary

MeasureTime frame
Pruritus 0,1,2 and 4 week Numerical rating scale,Excoriation 0,1,2 and 4 week Visual assessment of excoriation,Quality of life 0 and 4 week Dermatology Life Quality Index,Satisfaction 0 and 4 week 5 scale rating,Adverse events 1,2 and 4 week Causality assessment—

Countries

Thailand

Contacts

Public ContactAPIRAT RODJANONT

Srinakharinwirot University

apirat.rd@gmail.com085122-0842

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026